XML 51 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2022
Summary of Disaggregation of Revenues

The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):

 

 

 

Year Ended

 

 

Year Ended

 

 

Year Ended

 

 

 

December 31, 2022

 

 

December 31, 2021

 

 

December 31, 2020

 

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue,
   net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

124,996

 

 

$

941

 

 

$

125,937

 

 

$

61,870

 

 

$

-

 

 

$

61,870

 

 

$

36,030

 

 

$

-

 

 

$

36,030

 

CpG 1018
   adjuvant

 

 

-

 

 

 

587,708

 

 

 

587,708

 

 

 

-

 

 

 

375,229

 

 

 

375,229

 

 

 

-

 

 

 

3,277

 

 

 

3,277

 

Total product
   revenue, net

 

$

124,996

 

 

$

588,649

 

 

$

713,645

 

 

$

61,870

 

 

$

375,229

 

 

$

437,099

 

 

$

36,030

 

 

$

3,277

 

 

$

39,307

 

Other revenue

 

 

8,774

 

 

 

264

 

 

 

9,038

 

 

 

1,915

 

 

 

428

 

 

 

2,343

 

 

 

-

 

 

 

7,244

 

 

 

7,244

 

Total revenues

 

$

133,770

 

 

$

588,913

 

 

$

722,683

 

 

$

63,785

 

 

$

375,657

 

 

$

439,442

 

 

$

36,030

 

 

$

10,521

 

 

$

46,551

 

 

HEPLISAV-B  
Schedule of Revenues from Major Customers

The following table summarizes HEPLISAV-B product revenue from each of our three largest Customers (as a percentage of total HEPLISAV-B product revenue):

 

 

 

Year Ended

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Largest Customer

 

 

21

%

 

 

21

%

 

 

21

%

Second largest Customer

 

 

17

%

 

 

19

%

 

 

20

%

Third largest Customer

 

 

16

%

 

 

19

%

 

 

20

%

Summary of Product Revenue Allowance and Reserve Categories

 

 

Balance at
Beginning of
Period

 

 

Provisions
related to current
period sales

 

 

Credit or payments
made during
the period

 

 

Balance
at End of
Period

 

Year ended December 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves (1)

 

$

3,823

 

 

$

34,758

 

 

$

(30,402

)

 

$

8,179

 

Revenue reserve accruals (2)

 

$

8,253

 

 

$

24,806

 

 

$

(22,507

)

 

$

10,552

 

Year ended December 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves (1)

 

$

2,836

 

 

$

18,209

 

 

$

(17,222

)

 

$

3,823

 

Revenue reserve accruals (2)

 

$

6,040

 

 

$

13,077

 

 

$

(10,864

)

 

$

8,253

 

 

(1) Reserves are for chargebacks, discounts and other fees.

(2) Accruals are for returns, rebates and other fees.

CpG 1018  
Schedule of Revenues from Major Customers

The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):

 

 

 

Year Ended

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Largest collaboration partner

 

 

49

%

 

 

49

%

 

 

62

%

Second largest collaboration partner

 

 

35

%

 

 

24

%

 

 

36

%

Third largest collaboration partner

 

 

12

%

 

 

19

%

 

 

2

%

Summary of balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Additions (1)

 

 

Subtractions

 

 

Balance
at End of
Period

 

Year ended December 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset (2)

 

$

62,525

 

 

$

17,556

 

 

$

(8,116

)

 

$

71,965

 

Year ended December 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset

 

$

-

 

 

$

62,525

 

 

$

-

 

 

$

62,525

 

 

(1) Additions are revenues recognized for CpG 1018 adjuvant transferred to Clover that is reserved under the CEPI Agreement and for services performed under our agreement with the DoD.

(2) Includes $0.7 million of contract assets derived from our agreement with the DoD.

Summary of Deferred Revenue The following table summarizes balances and activities in our deferred revenue accounts (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Additions (1)

 

 

Subtractions (2)

 

 

Revenue recognized in the current period included in deferred revenue balance at the beginning of the period

 

 

Balance
at End of
Period

 

Year ended December 31,
   2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

349,864

 

 

$

45,596

 

 

$

(45,955

)

 

$

(349,505

)

 

$

-

 

Long-term deferred revenue

 

$

5,385

 

 

$

6,582

 

 

$

(11,967

)

 

$

-

 

 

$

-

 

Year ended December 31,
   2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

$

38,212

 

 

$

371,860

 

 

$

(21,996

)

 

$

(38,212

)

 

$

349,864

 

Long-term deferred revenue

 

$

-

 

 

$

168,467

 

 

$

(163,082

)

 

$

-

 

 

$

5,385

 

 

(1) Additions are primarily payments received or invoices issued before we satisfy our performance obligations.

(2) Subtractions are primarily revenues recognized in the period and reclassification from long-term deferred revenue to CEPI accrual.